Ivabradine for Rate Control in Permanent Atrial Fibrillation

Completed · Phase 1

Conditions studied: Atrial Fibrillation, Atrial Fibrillation, Persistent

In brief

Ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative effects on hemodynamics and inotropy. The objective in this proof of concept study is to investigate the hypothesis that ivabradine will slow the ventricular response in patients with permanent atrial fibrillation and previously-implanted pacemakers.

Key facts

Study ID

NCT03987204

Run by

Yale University

People needed

4

Starts

2019-06-15

Expected to finish

2019-09-17

Last updated by the study team

2021-07-02

Who can join

Age: 21 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with stable blood pressures with permanent atrial fibrillation and implanted pacemaker pacing less than 50% of the time, with or without concomitant beta blocker or calcium channel blocker use

You may not qualify if…

• Patients with uncontrolled hypertension will be excluded
• To eliminate confounding effects, patients on Digoxin therapy will be excluded
• Patients on anti-arrhythmic therapy
• Patients with pre-excitation on EKG
• Patients who pace > 50% of the time
• Patients with severe Child-Pugh C hepatic impairment

Where it is running

• Yale New Haven Hospital — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.